BJGMC Clinical Research Team Exceeds 6,000 Participant Enrollments in 4 Years

Date: 08/03/2018

The Indo-JHU Clinical Research partnership at Byramjee Jeejeebhoy Government Medical College (BJGMC) in Pune, India, is on an enrollment roll. The team has enrolled more than 6,000 participants in clinical trials and epidemiological studies, with approximately 1,200 during the last year. Indo-JHU research is led by Dr. Vidya Mave, Dr. Nishi Suryavanshi, and Dr. Nikhil Gupte in collaboration with BJGMC Deans Ajay Chandanwale and Sameer Joshi, and several heads of department, including Drs. Sangle of Medicine, Bhosale of Obstetrics and Gynecology, Bharadwaj of Microbiology, Kinikar of Pediatrics, and Gaikwad of Chest Medicine.

According to BJGMC Clinical Research Site (CRS) Director Dr. Vidya Mave, “The growth in the numbers of studies and participants has presented challenges that the team has really risen to. Among contributions of more than dedicated 150 team members, we owe much of our participant recruitment and management success to effective community outreach led by Savita Kanade and truly impressive coordination of studies by Dr. Nishi Suryavanshi. The CRS team is making a difference, and we take pride in our site’s contributions.”

Access Full Article

Clinical Trials

A5327: Sofosbuvir + Ribavirin w/o Interferon for Treatment...

A5327 SWIFT-C is a Phase I, open-label, two-cohort clinical trial, in which between 44 and 50 acutely HCV-infected HIV-1...

Read More

A5300/P2003: PHOENIx Feasibility Study

Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial Design

Read More

HPTN 069: A Phase II Randomized, Double-Blind, Study of the...

HPTN 069 is a phase II, four-arm, multisite, randomized, double-blinded trial. To assess the safety and tolerability of four...

Read More

A5337: Safety and Efficacy of Sirolimus for HIV Reservoir...

When a person becomes infected with HIV the immune system (the system that helps fight infection) is weakened (partly because...

Read More

A5332: Randomized Trial to Prevent Vascular Events in HIV...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

Read More